Skip to content

Comparison of Platelet-Rich Plasma Dressing Versus Normal Saline Dressing for Chronic Non-Healing Ulcers

Comparison of Platelet-Rich Plasma Dressing Versus Normal Saline Dressing for Chronic Non-Healing Ulcers

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07420868
Enrollment
100
Registered
2026-02-19
Start date
2025-03-14
Completion date
2025-09-13
Last updated
2026-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Skin Ulcer, Diabetic Foot Ulcer

Keywords

Platelet Rich Plasma, Normal Saline Dressing, Wound Healing, Ulcer Area Reduction, Complete Epithelialization

Brief summary

This randomized controlled trial will compare platelet rich plasma dressing with normal saline dressing for the treatment of chronic non healing cutaneous ulcers, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other suitable chronic ulcers of at least six weeks duration. A total of 100 adults will be recruited from the Department of Dermatology, Multan Medical and Dental College, and allocated in a 1:1 ratio to receive either autologous platelet rich plasma dressing or normal saline dressing for six weeks, with both groups receiving the same standardized wound care package including debridement when indicated, infection control, moisture balance, and etiology specific supportive measures such as offloading or compression. The hypothesis is that platelet rich plasma dressing will lead to greater wound healing by supplying concentrated platelets and naturally occurring growth factors that support granulation tissue formation and re epithelialization. The primary outcome is the percentage reduction in ulcer area from baseline to the end of follow up, measured using standardized planimetry. Secondary outcomes include the proportion of ulcers achieving complete epithelialization within the follow up period, time to complete healing among ulcers that close, and change in pain scores during treatment.

Interventions

BIOLOGICALPlatelet Rich Plasma Dressing

Autologous platelet rich plasma prepared under aseptic conditions using a standardized double centrifugation method and applied evenly over the entire wound bed at scheduled dressing visits for 6 weeks, with interim secondary dressing changes as clinically indicated based on exudate, using the same secondary dressing type across participants.

Normal saline cleansing and sterile gauze dressing moistened with normal saline applied at scheduled dressing visits for 6 weeks, with additional dressing changes permitted if clinically indicated due to exudate soakage, and all changes documented.

Sponsors

Multan Medical And Dental College
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or above * Either gender * Chronic non healing cutaneous ulcer of at least 6 weeks duration * Ulcer etiology eligible for conservative dressing-based management, including * Diabetic foot, Venous leg and Pressure ulcer * Other chronic ulcers considered suitable by the treating dermatologist * Measurable index ulcer surface area suitable for standardized photography and planimetric assessment * Clinically acceptable wound bed after initial wound bed preparation * No requirement for urgent surgical reconstruction at enrolment * Ability to attend twice weekly dressing visits for 6 weeks * Provision of written informed consent

Exclusion criteria

* Suspected or proven malignant ulceration * Vasculitic or inflammatory ulcers requiring systemic immunosuppression * Pyoderma gangrenosum * Critical limb ischemia or severe perfusion compromise on clinical assessment, with vascular screening where feasible * Requirement for urgent revascularization * Active osteomyelitis requiring bony debridement * Exposed bone with high suspicion of osteomyelitis * Rapidly spreading soft tissue infection * Systemic sepsis * Hematological abnormalities making venesection or platelet rich plasma preparation unsafe, including * Clinically relevant platelet dysfunction * Known bleeding diathesis * Therapeutic anticoagulation where temporary interruption is not clinically appropriate * Pregnancy or lactation * Participation in another interventional wound trial * Inability to comply with follow up

Design outcomes

Primary

MeasureTime frameDescription
Percentage Reduction in Index Ulcer AreaBaseline to Week 6Percentage change in ulcer surface area from baseline to Week 6, measured by standardized planimetry using either transparent grid tracing or calibrated digital photography with software-based area calculation. The same measurement method will be applied consistently for each participant.

Secondary

MeasureTime frameDescription
Complete Epithelialization of the Index UlcerUp to Week 6Proportion of index ulcers achieving complete epithelialization (full wound closure) within the 6-week follow-up period, documented at scheduled visits.
Time to Complete Healing of the Index UlcerUp to Week 6Time (in days) from randomization/baseline to first documented complete epithelialization among index ulcers that achieve closure during follow-up.
Change in Ulcer-Related Pain ScoreBaseline and weekly assessments through Week 6Change in pain severity assessed using a Visual Analogue Scale from 0 to 10, recorded at baseline and at each follow-up visit, with change calculated from baseline to each subsequent visit and to Week 6.

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORSaba Amin

Multan Medical And Dental College

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026